Efficacy and Safety Profile of Oral Tofacitinib in Non-Segmental Vitiligo Authors: Soumya Jagadeesan, Neenu Prasad, Prasanna Duraiswamy, Vinitha Varghese Panicker Published: 2026 ABSTRACT Background:Vitiligo is a chronic disease that is often challenging to treat. Melanocyte destruction in vitiligo is mediated by immune pathways involving IFN-γ and CD8+ T cells. Tofacitinib, a Janus kinase (JAK) 1/3 inhibitor, can be a promising treatment for vitiligo due to its potential to inhibit IFN-γ signaling. We retrospectively reviewed the records of 16 patients (6 men, 10 women; mean age 39.7 years) with nonsegmental vitiligo refractory to conventional therapies who were treated with oral tofacitinib along with topical tacrolimus and phototherapy.Aims:To evaluate the efficacy and adverse effects of the JAK1/3 inhibitor, oral tofacitinib, in the treatment of nonsegmental vitiligo.Methods:We retrospectively reviewed the records of 16 patients (6 men, 10 women; mean age: 39.7 years) with nonsegmental vitiligo refractory to conventional therapies who were treated with oral tofacitinib along with topical tacrolimus and phototherapy. Improvement was assessed using Vitiligo Area Scoring Index (VASI) at weeks 6, 12, and 24. Hemogram, lipid profile, liver, and renal function tests were monitored during the treatment period.Results:Improvement was assessed using Vitiligo Area Scoring Index (VASI) at weeks 6, 12, and 24. Mean VASI scores improved from 5.038 at baseline to 1.269 at 24 weeks, with 13 patients (81.25%) achieving at least 50% improvement. Transient leukopenia was observed in 3 patients, and one patient developed palmar warts.Conclusions:Oral tofacitinib shows significant potential in the management of nonsegmental vitiligo, in patients unresponsive to conventional therapies especially in combination with phototherapy. No significant adverse effects were observed during the follow up period other than a transient leukopenia in three patients and palmar warts in one patient. Introduction Vitiligo is a chronic disease caused by autoimmune destruction of melanocytes, resulting in depigmentation of the skin. Vitiligo affects both adults and children and can be a source of significant psychosocial distress. Immune-mediated destruction of melanocytes in vitiligo has been shown to be driven by IFN-γ and CD8 + T cells. Repigmentation of lesions with current traditional treatment options tends to be variable, and treatment response is often unsatisfactory. Tofacitinib, a Janus kinase (JAK) 1/3 inhibitor, is a promising treatment for vitiligo due to its inhibition of IFN-γ signaling.[1] We studied 16 patients with nonsegmental vitiligo refractory to conventional immunosuppressive treatments who were treated with oral tofacitinib. Subjects and Methods We performed a record-based review of patients with non-segmental vitiligo who were treated off-label with oral tofacitinib. After institutional ethical approval, patient records were retrieved from the hospital electronic medical records system and analyzed. Patients with nonsegmental or unstable acrofacial vitiligo aged 14 years or older who had received oral tofacitinib for at least 24 weeks were included in the study. All patients underwent pretreatment screening for tuberculosis through chest radiographs and the interferon-gamma release assay (IGRA). Patients were followed up on a monthly basis. Vitiligo Area Severity Index (VASI) was assessed at baseline as well as at each follow-up visit. Complete hemogram, liver and renal functions tests, and fasting lipid profile were performed during each follow-up visit. Any adverse events during the treatment period were noted. Sixteen patients (male : female 1:1.6) with a mean age of 37.4 years (range 14–59 years) were included. The mean disease duration was 48 months. Seven patients had acrofacial vitiligo, and 9 patients had generalized vitiligo. All patients had previously demonstrated inadequate treatment response to at least one conventional systemic agent in addition to topical tacrolimus and phototherapy. All patients were treated with oral tofacitinib 5 mg twice daily along with topical tacrolimus. Phototherapy was concurrently administered to all patients except one. Results All patients noted some degree of improvement at 6 weeks. The mean VASI at baseline was 5.038 (SD: 5.14). The mean VASI at the end of 6 weeks, 12 weeks, and 24 weeks were 3.539 (SD: 3.44), 2.388 (SD: 2.25), and 1.25 (SD: 1.34), respectively. By 24 weeks, 13 patients (81.25%) achieved more than 50% improvement. In one patient who developed new lesions on 10 mg daily tofacitinib, the dose was increased to 15 mg/day at 8 weeks. Fifteen patients received regular phototherapy (14 – twice or thrice weekly narrow-band-ultraviolet-B (NBUVB) therapy and 1 – psoralen ultraviolet A (PUVA) therapy) [Figure 1]. Three patients experienced drop in total leukocyte count which improved on reducing the dose of tofacitinib. One patient developed palmar warts. No other adverse events were noted. Characteristics of the patients are presented in the Table 1. Clinical images of three patients showing repigmentation at the end of 24 weeks of oral Tofacitinib. (No histological or charts included) Table 1Clinical and therapeutic characteristics of the study patientsSexAreas involvedDisease duration (Years)Previous treatmentTofacitinib dose (per day)Photo- therapyVASIAdverse events Week 0Week 6Week 12Week 24FAF9TAC, AZA, SCS, NBUVB10 mgNBUVB2.312.041.340.075NilFG6TAC, AZA, SCS, NBUVB10 mgNBUVB0.520.310.20.2NilMG2TAC, AZA, SCS, NBUVB10 mgNBUVB0.90.70.20.025NilFG16TAC, AZA, SCS, PUVA10 mgPUVA15.2114.210.3NilMAF4TAC, NBUVB10 mgNBUVB3.072.11.040.135NilMG2TAC, AZA, SCS, NBUVB10 mgNBUVB16.811.28.64.22NilMAF5TAC, AZA, SCS, NBUVB10 mgNBUVB1.680.90.70.51NilFG12TAC, SCS, NBUVB10 mgNBUVB6.6254.32.11.175NilFG14TAC, SCS, NBUVB10 mgNBUVB1.0250.80.60.31NilFAF2TAC, TCS, NBUVB10 mgNBUVB3.1732.892.45NilMG3TAC, SCS, NBUVBInitiated at 10 mg, increased to 15 mg at 6 weeks, reduced to 7.5 mgNBUVB12.237.25.11.175LeucopeniaFG4TAC, SCS, NBUVB10 mgNBUVB4.873.22.92.36NilFAF34TAC, TCS, SCS, NBUVB10 mg, reduced to 7.5 mgNBUVB1.2850.90.70.475LeucopeniaFG4TAC, SCS10 mg, reduced to 7.5 mgNBUVB2.921.81.110.7LeucopeniaMAF10TAC, SCS, NBUVB10 mgNBUVB3.452.842.412.15NilFAF4TAC, SCS, NBUVB10 mgNIL4.564.344.123.75Palmar wartsAF - Acrofacial vitiligo, G - Generalised vitiligo, TAC - Topical tacrolimus, AZA - Azathioprine, SCS - Systemic corticosteroids, NBUVB - Narrow-band UVB, TCS - Topical corticosteroids, PUVA - Psoralen UVA Clinical and therapeutic characteristics of the study patients AF - Acrofacial vitiligo, G - Generalised vitiligo, TAC - Topical tacrolimus, AZA - Azathioprine, SCS - Systemic corticosteroids, NBUVB - Narrow-band UVB, TCS - Topical corticosteroids, PUVA - Psoralen UVA Discussion Pathogenesis of vitiligo is mediated by IFN-γ produced by CD8+ T cells. IFN-γ through JAK 1/2 induces expression of C-X-C motif chemokine 9/10 (CXCL9/10) by keratinocytes resulting in further recruitment of CD8+ T cells and melanocyte destruction. IL-15, which functions through JAK 1/3, is also implicated in the pathogenesis of vitiligo through the activation and maintenance of tissue resident memory T cells.[1] Tofacitinib, a JAK 1/3 inhibitor, is a promising treatment option for vitiligo as it can block the downstream signaling of these pathogenic cytokines. Current literature on the use of tofacitinib is vitiligo are limited to small studies and case reports, and there is a need for further data on its use in vitiligo.[234] We conducted this retrospective record-based analysis of 16 patients to study the efficacy and safety profile of oral tofacitinib in nonsegmental vitiligo. All 16 patients developed at least some degree of repigmentation, at 6 weeks. 81.25% patient had greater than 50% improvement in VASI by 24 weeks with one patient developing near-complete repigmentation at the end of 24 weeks. With the exception of one, all 15 patients received twice or thrice weekly phototherapy (14 on NB-UVB and 1 on PUVA). The patient who underwent PUVA demonstrated the greatest improvement at 24 weeks (VASI improvement from 15.2 to 0.3). The patient who did not undergo phototherapy had minimal reduction in VASI from 4.56 (at baseline) to 3.75 (at 24 weeks). Phototherapy may be crucial in enhancing the treatment response of tofacitinib, a theory supported by Liu et al.[4] In their study treating 10 vitiligo patients with tofacitinib, 5 noted repigmentation at sites of either sunlight exposure or NB-UVB. Suction blister sampling of the lesions showed inhibition of autoimmune response at both responding and nonresponding sites, implying the essential role of light for melanocyte regeneration. Tofacitinib was started at 5 mg twice daily, and the response was found to be maintained on the lower dose. Only one patient required dose escalation to 15 mg/day for 6 weeks to control disease activity, and later, the dose could be tapered to 10 mg/day and 5 mg/day over 12 weeks with excellent clinical response. In our study, 3 patients developed fall in leukocyte counts which improved on dose reduction. One patient developed palmar warts. We did not note any other adverse effects in the follow-up period. However, tofacitinib has been associated with serious adverse events such as thromboembolism, infections, malignancies, and gastrointestinal perforation, and careful long-term follow-up is mandatory. Limitations of the study are the small sample size and the retrospective nature. In conclusion, tofacitinib may be a promising treatment option for vitiligo, especially for patients resistant to conventional therapies; however, further studies with larger sample sizes and longer follow-up are required to assess the long-term efficacy and safety profile. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Conflicts of interest There are no conflicts of interest.